Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size

Ruimeng Shia School of Pharmacy, Hebei Medical University, Shijiazhuang, PR ChinaView further author information

Xueli Liub Pharmacology Laboratory, Hebei Research Institute of Pharmaceutical and Medical Device Inspection, Shijiazhuang, PR ChinaCorrespondence[email protected]
View further author information

Yajuan Wangc Research and Development Department, CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, PR ChinaView further author information

Meilu Panb Pharmacology Laboratory, Hebei Research Institute of Pharmaceutical and Medical Device Inspection, Shijiazhuang, PR ChinaView further author information

Shaoqin Wanga School of Pharmacy, Hebei Medical University, Shijiazhuang, PR ChinaView further author information

Lin Shib Pharmacology Laboratory, Hebei Research Institute of Pharmaceutical and Medical Device Inspection, Shijiazhuang, PR ChinaView further author information

Beibei Nic Research and Development Department, CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, PR ChinaView further author information

show all

Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size

Supplemental material.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size

Supplemental material.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date